Background: In the late 1990s, the use of high-dose chemotherapy (HDCT) and stem-cell rescue held promise for patients with advanced and poor prognosis germ-cell tumors (GCT). We started a randomized phase II trial to assess the efficacy of sequential HDCT compared with cisplatin, etoposide, and bleomycin (PEB).
proportion of 16% of patients presenting with an advanced disease [1] . Since 1987, the standard therapy of these patients is represented by four cycles of cisplatin, etoposide, and bleomycin (PEB) followed by surgical clearance of residual resectable disease [2] .
Many futile attempts have been undertaken in the last two to three decades to improve the outcomes in this subgroup of patients, including the use of either double-dose cisplatin regimens, dose-dense schedules or the use of etoposide, ifosfamide, and cisplatin (VIP) [3] [4] [5] [6] [7] .
The promising results of upfront high-dose chemotherapy (HDCT) from early phase II trials as well as from several retrospective series in GCT were not confirmed by larger phase III trials subsequently reported [8] [9] [10] [11] [12] . We present the long-term results of an original approach of sequential HDCT given upfront in patients with poor prognosis GCT at Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.
patients and methods eligibility Eligibility included male patients having a histological or clinical diagnosis of advanced GCT, and classified in the IGCCCG poor prognostic category. Prior chemotherapy in adjuvant setting, presence of underlying major comorbidities, or inadequate organ function that could have precluded the inclusion in the HDCT arm were the principal exclusion criteria.
The study was approved by the Institutional Review Board of the sponsoring institution (Fondazione IRCCS Istituto Nazionale dei Tumori) and by the ethics committee of each participating center and all patients provided written informed consent.
study design and treatment assignment
This was a randomized, multicentric, phase II investigator-initiated trial. Patients were randomly assigned (1 : 1 ratio) to receive four cycles of PEB (arm A) or two cycles of PEB followed by a high-dose sequential original articles Annals of Oncology chemotherapy (HDS, arm B). Randomization was carried out at the centralized trial office of the sponsor institution using the method of random permutated block, with treatment center as a stratification factor. Study schema is provided in supplementary Figure S1 , available at Annals of Oncology online.
In arm A, patients received the standard treatment consisting of four cycles of PEB, every 3 weeks. In arm B, after initial two cycles of PEB, patients were assigned to receive a single course of high-dose cyclophosphamide (i.e. 7.0 g/m 2 ) followed by peripheral CD34+ cell harvest, two cycles cisplatin (100 mg/m 2 ) plus high-dose etoposide (2.4 g/m 2 each) with stemcell support preceding the administration of a single HDCT course with carboplatin (CBDCA) AUC 27 mg/ml × min followed by autologous stem-cell transplant. Each course was planned to be administered at the occurrence of hematopoietic recovery (ideally within 4 weeks) and all patients in arm B received granulocyte (macrophage) colony-stimulating factor during the multiple recovery periods. Baseline assessments included complete blood cells count and biochemical panel, serum tumor markers [STM, α-fetoprotein (AFP), beta-human choriogonadotropin (HCG), and lactate dehydrogenase], and a total body computed tomography (CT) scan. STM measurement was planned before each cycle of chemotherapy while imaging restaging at the end of chemotherapy (arm A), preceding HD-CBDCA, and after transplant (arm B).
Definitions of complete response (CR), partial response (PR) with negative markers (PRm−), PR-positive markers (PRm+), and stable disease (SD) have been described elsewhere [13] .
Postchemotherapy surgery was planned for all patients with a PR that was amenable to radical extirpation (i.e. including patients with incomplete decrease of STM). Patients achieving a CR or yielding an unresectable PRm− underwent surveillance, while those having an unresectable PRm+ or a PD started a second-line therapy. No further treatments were provided after radical surgery.
Patients who achieved a CR, PR, or SD were not considered to have had an event in the progression-free survival (PFS) analysis until they developed evidence of disease progression, defined by rising STM, increasing size of non-teratomatous tumor masses or development of new tumor masses. Side-effects were graded according to the updating versions of the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) [14] . The trial was registered with ClinicalTrials.gov, number NCT02161692.
statistical analysis
The primary end point of the trial was PFS, defined as the time from randomization to documented progression or death. Patients alive and without evidence of progression were censored on the date of last contact. The study was designed to have 80% power in detecting a 30% improvement in 5-year PFS, from 40% to 70% (corresponding to a 61% relative hazard reduction), given a two-sided 5% significance level; the overall number of events to be recorded in order to achieve the stated power was 35. Secondary end points were overall response rate, overall survival (OS), and safety. OS was defined as the time from randomization to last follow-up or death from any cause. Statistical analysis was carried out according to the intent-to-treat (ITT) principle. Exact 95% confidence interval (CI) of response proportion in each trial arm was calculated based on the binomial distribution, and betweenarm comparison was based on Pearson's χ 2 test. Plots of PFS and OS were obtained with the Kaplan-Meier method and compared with the log-rank test. Multivariable analyses based on Cox regression models were also undertaken to jointly investigate the following pre-specified factors: treatment arm and the covariates tumor primary site, presence of liver, bone, or brain (LBB) metastases, AFP and HCG levels above or equal/below 1000 (IU/ml and IU/l, respectively). In this way, we could estimate the covariate-adjusted treatment effect on PFS and OS, and obtain as well forest plots by including interaction terms between treatment and singly taken covariates in the models. The analyses were carried out using the SAS® and R software (http:// www.r-project.org/, last accessed 20 June 2014) and the results were considered statistically significant whenever a two-sided P value <5% was achieved.
results
patients characteristics and safety
From December 1996 to March 2007, 85 patients were randomly assigned in arm A (n = 43) and arm B (n = 42) as provided in Figure 1 . Baseline patient and disease characteristics were balanced in the two arms except for higher median values of elevated AFP and HCG, as detailed in Table 1 . Treatment adherence in HDS arm was high and five patients only did not receive HD-carboplatin because of disease progression (n = 4) or failure to mobilize hematopoietic stem cells (n = 1). The median duration of treatment was 4.6 months [interquartile range (IQR): 4-4.8] in this arm. As expected, acute toxicity was more severe in arm B as presented in Table 2 , although one case of treatment-related death (septic shock) was recorded in PEB arm. All patients who received transplantation had a full hematopoietic recovery and no cases of severe late toxicities, second cancers, or myelodisplasia have been observed.
response and survival
Complete response to chemotherapy was achieved in 2 (4.6%) and 4 patients (9.5%) in arm A and B, respectively, while PRm− in 26 (60.5%) and 25 (59.5%) patients ( Figure 2A ). Five-year OS was 62.8% (95% CI 49.9% to 79.0%) and 59.3% (95% CI 46.1% to 76.3%) in the two arms (P = 0.686, Figure 2B ). Thirty-three and 25 patients underwent postchemotherapy surgery in arm A and arm B, respectively, and a comparable number of cases yielding viable cancer in residuals was found (30.3% and 36.0% in the two arms).
On multivariable analysis, the presence of LBB metastases was significantly associated with PFS [hazard ratio (HR): 2.21, 95% CI 1.04-4.70, P = 0.040, supplementary Table S1 , available at Annals of Oncology online] while no significant predictor for OS, including treatment arm, was observed. Subgroup analyses for PFS and OS are shown in Supplementary Figure S2A and B, available at Annals of Oncology online, respectively. Patients having baseline AFP levels ≤1000 IU/ml mostly benefited from HDS in the OS analysis (P = 0.049), whereas no significance in the analysis for PFS was found.
discussion
In this multicentric randomized phase II trial, we were not able to demonstrate a survival advantage with the use of a doseintensified sequential therapy in patients with poor prognosis GCT. Survival estimates were comparable irrespective of the prognostic features. These results represent a further step toward the allocation of HDCT in the therapeutic strategy of GCT. Until new drugs or new concepts become available, further attempts using HDCT to improve results in this patient category should be discouraged. The use of conditioning regimens different from the current standard of care in the salvage setting (i.e. double or triple carboplatin and etoposide course) is indeed a major limitation of the present trial. In detail, the following biases should be accounted for when interpreting present results. First, the addition of high-dose cyclophosphamide in the treatment of GCT actually failed to provide successful results in multiple subsequent trials and further administration in this disease should be discouraged. Secondly, results from trials of HDCT in the salvage setting proved the superiority of multiple courses of carboplatin and etoposide over either a single-course or a single-drug strategy, and the former is currently the recommended conditioning regimen [15, 16] . Thirdly, and most importantly, while there is no doubt regarding the indication of HDCT whenever at least one chemotherapy regimen has failed (i.e. any salvage setting when feasible), negative findings did not support the use of HDCT as an earlier consolidation. The use of HDCT given upfront in disseminated GCT was deeply investigated in several phase II trials carried out in the decade 1990-2000 and early results seemed to be promising. US and German trials as well as a multivariate matched-pair analysis suggested a potential for 20% improvement in survival over conventional-dose chemotherapy in the first-line setting [8] [9] [10] 17] .
However, these results were not confirmed in a large phase III trial comparing four cycles of PEB with two courses of PEB followed by two cycles of high-dose carboplatin, etoposide, and cyclophosphamide (CEC) in intermediate and poor prognosis GCT [11] . Another phase III trial sponsored by the Groupe d'Etude des Tumeurs Urogénitales (GETUG) failed to demonstrate a superiority of a HDCT approach over the standard-dose combination of etoposide and double-dose cisplatin with vinblastine and bleomycin (PVeBV) [12] .
Another important issue is relative to the survival results with PEB in this prognostic category. A step-wise improvement of survival in patients with poor prognosis GCT is a recognized phenomenon, mainly attributable to the therapeutic improvements in the salvage setting [18] . Present results however showed exceptionally high PFS rates in the standard-dose arm (i.e. 5-year PFS exceeding 55%), partly attributable to the effect of patient selection within the poor prognostic category (19 patients only with primary mediastinal GCT have been recruited, and the proportion of patients yielding LBB metastases was a rather low). Indeed, the better than reported results from previous series in the conventional-dose arm may equally be the result of treatment at expert centers able to deliver high-quality care for these rare tumors.
These results have been confirmed in a recent analysis of the entire series of poor prognosis GCT treated at Fondazione INT, Milan, where the vast majority of patients (87%) have been recruited, the global picture being that of a very high cure-rate irrespective of the treatment period (years 1982-2013) [19] . Indeed this benchmark of conventional-dose chemotherapy was a major issue against the study assumptions and contributed to the negative findings.
Survival estimates with PEB as well as the slow accrual rate of present and other similar trials are the reasons why the strategy of personalizing treatment based on IGCCCG category has failed. In the poor prognostic category, if the expected 40% PFS rate could still be an issue in favor of a randomized trial, the latter is hardly conceivable with an improvement to 56% in conventional-dose arm, and because of the rarity of such cases. This also applies to the intermediate prognosis category, for which a phase III study of the European Organisation for the Research and Treatment of Cancer (EORTC) comparing paclitaxel-PEB to standard PEB has failed to meet the target number of patients [20] . An alternative strategy to improve results in the first-line setting was to shape treatments based on the kinetics of tumor marker decline. In patients with a slow decline, the use of HDCT was beneficial over PEB in the phase III United States Intergroup trial, and the results of GETUG13 trial aligned with these findings [11, 21] . In the present study, no subanalyses based on early response have been planned, and the sample size of this phase II trial could hardly accommodate reliable subgroup analyses of any kind.
To summarize, present long-term results of a phase II trial of HDS compared with PEB did provide an additional argument in favor of administering standard chemotherapy in poor prognosis GCT. Present and available findings suggest that IGCCCG prognostic classification is not a reliable tool for selecting patients to clinical trials and that attempts to improve the outcome in the first-line setting should rely on the earlier use of effective salvage regimens.
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